Could the Combined Administration of Bone Antiresorptive Drug, Taxanes, and Corticosteroids Worsen Medication Related Osteonecrosis of the Jaws in Cancer Patients?

Table 1

Patients characteristics: gender, frequency of cancer location, frequency of oncologic drugs other than zoledronic acid, frequency of MR-ONJ location, presence/absence of oral trigger, and presence/absence of suppuration among subjects who developed osteonecrosis of the jaws.

	(%)
Gender
Female	36 (62%)
Male	22 (38%)
Cancer location
Breast cancer	38 (65,5%)
Prostate cancer	16 (27,5%)
Lung cancer	3 (5%)
Nasopharynx cancer	1 (2%)
Other therapies
Docetaxel	38 (65,5%)
Paclitaxel	25 (43%)
Bevacizumab	14 (24%)
Denosumab	9 (15,5%)
ONJ location
Mandibular	43 (74%)
Maxilla	10 (18%)
Mandibular/Maxilla	5 (9%)
Oral trigger
Absence	22 (38%)
Presence	36 (62%)
Suppuration
Absence	21 (36%)
Presence	37 (64%)